Sino Biopharmaceutical Limited (HKG:1177)
5.26
-0.19 (-3.49%)
Sep 1, 2026, 4:08 PM HKT
Sino Biopharmaceutical Employees
Sino Biopharmaceutical had 22,838 employees as of June 30, 2026. The number of employees decreased by 218 or -0.95% compared to the same quarter last year.
Employees
22,838
Change
-218
Growth
-0.95%
Revenue / Employee
1.70M HKD
Profits / Employee
120.78K HKD
Market Cap
93.68B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 22,838 | -218 | -0.95% |
| Dec 31, 2025 | 21,435 | -2,944 | -12.08% |
| Jun 30, 2025 | 23,056 | - | - |
| Dec 31, 2024 | 24,379 | -1,427 | -5.53% |
| Dec 31, 2023 | 25,806 | -466 | -1.77% |
| Dec 31, 2022 | 26,272 | 693 | 2.71% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| WuXi Biologics | 14,705 |
| BeOne Medicines AG | 12,000 |
| Innovent Biologics | 8,754 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
Sino Biopharmaceutical News
- 13 days ago - Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion - PRNewsWire
- 13 days ago - Sino Biopharmaceutical Earnings release: H1 2026 - Filings
- 7 weeks ago - Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs - Reuters
- 7 weeks ago - AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal - WSJ
- 7 weeks ago - Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion - Reuters
- 4 months ago - GSK enters into exclusive strategic collaboration with Sino Biopharm - TheFly
- 4 months ago - GSK to team up with Sino Biopharma for China launch of hepatitis B treatment - Reuters
- 5 months ago - Sino Biopharmaceutical Earnings release: H2 2025 - Filings